Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy
Open Access
- 27 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (6) , 1525-1532
- https://doi.org/10.1002/hep.20198
Abstract
Replication-competent herpes simplex oncolytic viruses are promising anticancer agents that partly target increased DNA synthesis in tumor cells. Investigators have proposed that these DNA viruses may be combined with liver resection to enhance killing of liver malignancies. Whether or not the cellular alterations associated with hepatic regeneration affect the efficacy and toxicity of these promising anticancer agents is unknown. This study examined the behavior of two oncolytic viruses, NV1020 and G207, during liver regeneration. When delivered during the peak of liver regeneration, replication and appearance of both G207 and NV1020 in hepatic tissue are enhanced as demonstrated by histochemical staining for the marker gene lac Z, immunohistochemical staining, and quantitative polymerase chain reaction. This increased appearance of virus in liver tissue correlates with increases in cellular ribonucleotide reductase activity and DNA synthesis and is also associated with increased viral binding. However, increased viral presence is transient, and viral detection declines to baseline within 7 days. When these viruses were delivered to animals even as early as 7 days after hepatectomy, there proved to be no measurable viral replication in any organ and no increased morbidity or mortality. In conclusion, the early stages of hepatic regeneration after resection provide an environment suitable for viral replication. Administration of replication-competent herpes simplex virus during the peak of hepatocyte regeneration (24-48 hours) permits viral productivity in tissue that otherwise does not support viral growth. The increase in hepatotoxicity after hepatectomy is short-lived and can be predicted by peak hepatocyte DNA synthesis. (Hepatology 2004;39:1525-1532.)Keywords
This publication has 35 references indexed in Scilit:
- Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic modelThe FASEB Journal, 2001
- Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral TherapyHuman Gene Therapy, 2000
- Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex VirusHuman Gene Therapy, 1999
- Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1Human Gene Therapy, 1998
- Partial hepatectomy accelerates local tumor growth: Potential roles of local cytokine activationSurgery, 1998
- Liver resection for colorectal metastases.Journal of Clinical Oncology, 1997
- Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.Journal of Clinical Investigation, 1997
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)The Journal of Infectious Diseases, 1990
- Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutantVirology, 1988
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in RodentsThe Journal of Infectious Diseases, 1988